Trials / Withdrawn
WithdrawnNCT04898348
A Study to Investigate Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Mild to Moderate Active Ulcerative Colitis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- KoBioLabs · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to investigate efficacy and safety of KBL697 in patients with mild to moderate active ulcerative colitis. KBL697 has been developed as a potential new treatment for ulcerative colitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KBL697 | 3 capsules twice a day dosing of KBL697 |
| DRUG | Placebo | 3 capsules twice a day dosing of Placebo |
Timeline
- Start date
- 2022-01-14
- Primary completion
- 2023-07-28
- Completion
- 2023-07-28
- First posted
- 2021-05-24
- Last updated
- 2023-08-02
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04898348. Inclusion in this directory is not an endorsement.